Cough, Expiratory Training, and Chronic Aspiration After Head and Neck Radiotherapy
Head and Neck Cancer
About this trial
This is an interventional supportive care trial for Head and Neck Cancer focused on measuring Head and Neck Cancer, Post-radiotherapy H&N cancer survivors, Aspiration, Expiratory muscle strength training, EMST, Dysphagia therapy, Modified barium swallow, Neurocognitive exams, Questionnaires, Surveys, Digital Manometer
Eligibility Criteria
Inclusion Criteria:
- Age >/= 18 years
- History of curative-intent radiotherapy at MDACC for a new primary H&N cancer in past 15 years
- Referred to Section of Speech Pathology and Audiology for swallowing evaluation
- Ability to understand and willingness to sign written informed consent
Exclusion Criteria:
- History of recurrent or second primary H&N, central nervous system, or thoracic cancer at time of modified barium swallow (MBS) study
- Prior H&N surgery excluding diagnostic procedures, transoral surgery, or non-radical neck dissection
- History of functionally limiting chronic or acute cardiac, pulmonary, or neuromuscular disease
- Tracheotomy or oxygen dependence at time of MBS
- Patients with Mini-Mental State Examination (MMSE) <24 will be ineligible for participation in the therapeutic trial
Sites / Locations
- University of Texas MD Anderson Cancer Center
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Aspirators Group
Non-Aspirators Group
Participants receive modified barium swallow at baseline and after 8 weeks of using the expiratory muscle strength training (EMST) device. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study. Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks. Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device.
Participants receive modified barium swallow at baseline. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline and at 12 months.